News & Events

Press Releases

Show All

April 2010

April 27, 2010 Cellular Dynamics Raises $40.6 MM to Revolutionize Pharma Drug Research with Industrial Manufacture of Human Heart and Other CellsDownload PDF

MADISON, Wis., April 27, 2010 – Cellular Dynamics International, Inc. (CDI), already the world’s highest volume manufacturer of human heart cells, has closed on a $40.6 million Series B private equity round. This financing enables the company to increase production capacity for its iCellTMCardiomyocytes, human heart cells derived from induced pluripotent stem cells (iPSCs), and to launch additional human tissue cell products for biomedical and pharmaceutical drug development and safety research.

April 21, 2010 Cellular Dynamics International’s iCellTM Cardiomyocytes, Derived From Human iPSCs, Named to MIT Technology Review’s Annual 10 Emerging Technologies ListDownload PDF

MADISON, Wis., April 21, 2010 – Cellular Dynamics International (CDI) today announced that CDI’s development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review’s Annual 10 Emerging Technologies List.